Status:
NOT_YET_RECRUITING
Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
Lead Sponsor:
Marc Blondon
Conditions:
Venous Thromboembolism (VTE)
Postpartum
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main quest...
Eligibility Criteria
Inclusion
- postpartum women after delivery AND ≥1 major risk factor / ≥2 minor risk factors:
- Major risk factors: Emergency cesarean section ; Pre-pregnancy BMI ≥35kg/m2 ; Known low-risk thrombophilia (heterozygous factor V Leiden; heterozygous G20210 prothrombin mutation) ; Pre-eclampsia ; Pre-term delivery ; Peripartum systemic infection ; Intra-uterine growth restriction ; Pregnancy loss
- Minor risk factors: Age ≥35 years ; Pre-pregnancy BMI 30.0-34.9kg/m2 ; Current smoking ; Elective cesarean section ; Postpartum hemorrhage ; Antenatal immobility
Exclusion
- ≥2 doses of postpartum LMWH
- Any indication for therapeutic anticoagulation
- A high-risk of postpartum VTE
- An increased bleeding risk
- A contra-indication to heparin
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2030
Estimated Enrollment :
9200 Patients enrolled
Trial Details
Trial ID
NCT07140211
Start Date
September 1 2025
End Date
August 1 2030
Last Update
September 12 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.